ArticleInfectious diseases & clinical microbiology2025
Comprehensive Molecular Epidemiology of HPV in a High-Volume Tertiary Center.
Article in Infectious diseases & clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Human papillomavirus (HPV) is a double-stranded DNA virus and the leading cause of cervical cancer. More than 230 genotypes have been identified and classified as high-risk (HR) or low-risk (LR) based on their oncogenic potential. Despite the availability of prophylactic vaccines against major HR-HPV types, regional genotype variations and limited public awareness remain major barriers to cervical cancer prevention. This study aimed to retrospectively assess HPV positivity, genotype distribution, and treatment outcomes among women attending a tertiary care center. Materials and Methods: Cervical swab samples from women aged 18 years and older, collected between January 2023 and December 2024, were analyzed by real-time polymerase chain reaction (PCR) for the detection and genotyping of HPV DNA. Human papillomavirus positivity was defined as the detection of HPV16, HPV18, or other HR-HPV (OHR-HPV) types. Demographic and clinical data were retrieved from the hospital information system. Statistical analyses included descriptive statistics, chi-square tests, and linear regression, performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Results: Of 7009 samples analyzed, 11.30% (792/7009) were HPV positive: OHR-HPV (66.79% [529/792]), HPV16 (15.28% [121/792]), and HPV18 (5.81% [46/792]). The mean age of HPV-positive patients was 38.59 years. Positivity was highest in the 18-19 age group (33.33% [6/18]) and declined significantly with age ( Conclusion: This study provides comprehensive epidemiological data on HPV genotype distribution, age-related trends, and post-treatment outcomes in a tertiary care center. The high prevalence of non-vaccine-covered HR-HPV types underscores the need to expand vaccination strategies and enhance public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.